ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.

Manuel Weber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.